Comparing Maze Therapeutics (NASDAQ:MAZE) and Septerna (NASDAQ:SEPN)

Maze Therapeutics (NASDAQ:MAZE – Get Free Report) and Septerna (NASDAQ:SEPN – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

Risk & Volatility

Maze Therapeutics has a beta of 2.04, meaning that its stock price is 104% more volatile than the S&P 500. Comparatively, Septerna has a beta of 2.2, meaning that its stock price is 120% more volatile than the S&P 500.

Profitability

This table compares Maze Therapeutics and Septerna’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Maze Therapeutics N/A -38.39% -32.57%
Septerna -61.29% -14.98% -10.03%

Earnings and Valuation

This table compares Maze Therapeutics and Septerna”s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Maze Therapeutics $20.00 million 93.69 -$131.12 million ($2.65) -12.93
Septerna $96.27 million 20.50 -$48.88 million ($1.29) -32.18

Septerna has higher revenue and earnings than Maze Therapeutics. Septerna is trading at a lower price-to-earnings ratio than Maze Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations for Maze Therapeutics and Septerna, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Maze Therapeutics 1 0 9 3 3.08
Septerna 1 1 8 1 2.82

Maze Therapeutics currently has a consensus price target of $65.50, indicating a potential upside of 91.16%. Septerna has a consensus price target of $56.44, indicating a potential upside of 35.98%. Given Maze Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Maze Therapeutics is more favorable than Septerna.

Summary

Maze Therapeutics beats Septerna on 7 of the 13 factors compared between the two stocks.

About Maze Therapeutics

(Get Free Report)

Maze Therapeutics is a clinical-stage biotechnology company developing precision medicines for people with serious diseases. Its research uses human genetics and functional genomics to identify disease-related biological pathways and potential drug targets. The company’s Maze Compass platform is designed to connect genetic insights with biological research to guide drug discovery and development. Its investigational programs have included approaches for APOL1-mediated kidney disease and Pompe disease; these are not marketed treatments.

About Septerna

(Get Free Report)

Septerna is a clinical-stage biotechnology company developing medicines that target G protein-coupled receptors (GPCRs), a large family of proteins involved in many biological processes. The company is based in South San Francisco, California. Its discovery platform is designed to identify drug candidates that act on GPCRs, including targets that have been difficult to address with conventional drug-development approaches. Septerna is advancing candidates for endocrine, metabolic and other disease areas, with an emphasis on small-molecule medicines.

Receive News & Ratings for Maze Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maze Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.